| Patent Number |
Title Of Patent |
Date Issued |
| 7214697 |
2-Oxo-benzimidazolyl substituted ethanolamine derivatives and their use as .beta..sub.3 agonists |
May 8, 2007 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula (I), wherein R is C.sub.3 C.sub.8 alkyl or (C.sub.3 C.sub.7 cycloalkyl)C.sub.1 C.sub.5 alk-di-yl: R.sup.1 is H, CN, halo; C.sub.1 C.sub.6 alkyl, C.sub.1 C.sub.4 haloalkyl, CO.sub.2 R.sup.6, CONR.su |
| 7208505 |
.beta.3 adrenergic agonists |
April 24, 2007 |
| The present invention relates to a .beta.3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful, e.g., for treating Type 2 diabetes and/or obesity ##STR00001## |
| 7122680 |
3-Substituted oxindole .beta..sub.3 agonsists |
October 17, 2006 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula I: ##STR00001## or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity. |
| 7087635 |
3-substituted oxindole .beta.3 agonists |
August 8, 2006 |
| The present invention relates to a .beta.3 adrenergic receptor agonist of formula I: ##STR00001## or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. |
| 7009060 |
2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as .beta..sub.3 agonists |
March 7, 2006 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula I: ##STR00001## or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. |
| 6911463 |
3-substituted oxindole .beta.-3 agonists |
June 28, 2005 |
| The present invention relates to a .beta.3 adrenergic receptor agonist of formula (I); or a pharmaceutical salt thereof; which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type 2 diabetes and/or obesity. |
| 6881733 |
Serotonergic benzofurans |
April 19, 2005 |
| The present invention provides serotonergic benzofurans of Formula (I): where A, R, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as described in the specification. ##STR1## |
| 6825220 |
3-Substituted oxindole .beta. 3 agonists |
November 30, 2004 |
| The present invention relates to a .beta.;3 adrenergic receptor agonist of formula I: (1); or a pharmaceutical salt thereof; which is useful for treating Type II diabetes and/or obesity. |
| 6730792 |
.beta.3 adrenergic agonists |
May 4, 2004 |
| The present invention relates to a .beta..sub.3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and/or obesity. The compound can a |
| 6265581 |
Selective .beta.3 adrenergic agonists |
July 24, 2001 |
| The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention prov |
| 6093735 |
Selective .beta.-3 adrenergic agonists |
July 25, 2000 |
| The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention prov |
| 6075040 |
Selective .beta..sub.3 adrenergic agonists |
June 13, 2000 |
| The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention prov |
| 5977154 |
Selective .beta.3 adrenergic agonist |
November 2, 1999 |
| The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention prov |
| 5840738 |
Selective .beta.-3 adrenergic agonists |
November 24, 1998 |
| The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity. The invention prov |
